Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38
Selected Variant
HY-171738
Size: 1 Each
Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 is an antibody-drug conjugate (ADC) consisting of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab conjugated to the linker Mc-VC-PAB and the topoisomerase I inhibitor SN38 (HY-13704). The ADC toxic molecule and linker part are Mc-VC-PAB-SN38 (HY-131057). Anti-SLC34A2 (Lifastuzumab) -MC-Vc-PAB-SN38 can be used in cancer research[1][2].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Sodium Channel; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Anti-SLC34A2(Lifastuzumab)-MC-Vc-PAB-SN38]
References & Citations
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Topo I
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Beta-2 Microglobulin (B2M) (BBM.1), 0.2mg/mL
Nucleophosmin (Acute Myeloid Leukemia Marker) (NPM1/1902), Biotin conjugate, 0.1mg/mL
Human recombinant 4-1BBL (4-1BB ligand) protein, AF
